Axsome Therapeutics, Inc. - Common Stock, $0.0001 par value per share (AXSM) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2015 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
AXSM on Nasdaq
Shares outstanding
48,932,355
Price per share
$182.64
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
37,163,707
Total reported value
$4,512,702,432
% of total 13F portfolios
0.01%
Share change
-703,541
Value change
-$68,301,545
Number of holders
350
Price from insider filings
$182.64
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Axsome Therapeutics, Inc. - Common Stock, $0.0001 par value per share (AXSM) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RTW INVESTMENTS, LP 3.1% -48% $177,462,482 -$164,467,584 1,516,903 -48% RTW Investments, LP 30 Jun 2025

As of 30 Sep 2025, 350 institutional investors reported holding 37,163,707 shares of Axsome Therapeutics, Inc. - Common Stock, $0.0001 par value per share (AXSM). This represents 76% of the company’s total 48,932,355 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Axsome Therapeutics, Inc. - Common Stock, $0.0001 par value per share (AXSM) together control 50% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 8.5% 4,180,646 +6% 0.01% $507,739,457
BlackRock, Inc. 7.7% 3,790,929 -1.1% 0.01% $460,408,328
WELLINGTON MANAGEMENT GROUP LLP 2.7% 1,334,560 +84% 0.03% $162,082,313
RTW INVESTMENTS, LP 2.3% 1,118,883 -26% 1.7% $135,888,340
MACQUARIE GROUP LTD 2.2% 1,084,536 -4.7% 0.15% $131,717,000
PRICE T ROWE ASSOCIATES INC /MD/ 2.1% 1,037,448 +69% 0.01% $125,999,000
GEODE CAPITAL MANAGEMENT, LLC 2% 997,700 +0.83% 0.01% $121,188,899
Invesco Ltd. 2% 990,557 +73% 0.02% $120,303,148
STATE STREET CORP 1.9% 942,960 -1.6% 0% $114,522,492
FMR LLC 1.9% 927,883 -5% 0.01% $112,691,333
Deep Track Capital, LP 1.8% 900,000 +12% 3.1% $109,305,000
Fairmount Funds Management LLC 1.7% 815,176 0% 8.9% $99,003,125
EVENTIDE ASSET MANAGEMENT, LLC 1.5% 746,398 +2.9% 1.5% $90,637,842
ALETHEA CAPITAL MANAGEMENT, LLC 1.4% 670,883 +0.53% 52% $81,478,740
ORBIMED ADVISORS LLC 1.1% 531,800 +24% 1.5% $64,587,110
PFM Health Sciences, LP 1.1% 530,332 +9.8% 5.5% $64,408,821
BVF INC/IL 0.99% 486,757 -71% 2.4% $59,116,638
ADAGE CAPITAL PARTNERS GP, L.L.C. 0.91% 445,000 -0.45% 0.09% $54,045,250
MORGAN STANLEY 0.84% 409,580 -8.6% 0% $49,743,576
NORTHERN TRUST CORP 0.84% 409,535 +0.03% 0.01% $49,738,025
Sofinnova Investments, Inc. 0.8% 393,499 +320% 2.9% $47,790,454
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.78% 382,047 +7.1% 0.01% $46,399,608
MARSHALL WACE, LLP 0.77% 378,024 +567% 0.05% $45,911,016
PRINCIPAL FINANCIAL GROUP INC 0.75% 368,434 +3.6% 0.02% $44,746,308
Pictet Asset Management Holding SA 0.74% 362,138 -12% 0.04% $43,981,660

Institutional Holders of Axsome Therapeutics, Inc. - Common Stock, $0.0001 par value per share (AXSM) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 780,997 $142,406,885 +$35,732,294 $182.64 30
2025 Q3 37,163,707 $4,512,702,432 -$68,301,545 $121.45 350
2025 Q2 37,843,872 $3,950,044,159 +$74,087,676 $104.39 345
2025 Q1 36,999,749 $4,315,368,350 +$55,229,713 $116.63 349
2024 Q4 37,175,137 $3,145,105,310 -$143,165,249 $84.61 290
2024 Q3 38,284,012 $3,439,678,679 -$222,044,855 $89.87 279
2024 Q2 40,709,286 $3,277,008,054 +$196,462,798 $80.50 255
2024 Q1 38,345,460 $3,058,853,247 -$38,325,229 $79.80 253
2023 Q4 89,106 $7,092,277 +$1,410,892 $79.59 5
2023 Q3 37,648,168 $2,631,134,803 +$88,107,539 $69.89 219
2023 Q2 36,139,983 $2,596,808,610 +$315,515,613 $71.86 222
2023 Q1 31,880,496 $1,965,841,502 +$94,622,475 $61.68 190
2022 Q4 30,012,634 $2,314,764,886 +$389,630,107 $77.13 207
2022 Q3 24,732,632 $1,103,457,640 +$176,767,742 $44.62 175
2022 Q2 21,223,505 $812,550,315 +$86,593,238 $38.30 159
2022 Q1 18,967,490 $781,598,956 +$21,550,119 $41.39 160
2021 Q4 18,486,136 $698,385,239 -$17,626,062 $37.78 155
2021 Q3 18,612,104 $612,460,207 -$186,365,962 $32.96 162
2021 Q2 22,368,097 $1,508,361,537 -$37,374,555 $67.46 174
2021 Q1 22,937,333 $1,299,683,826 -$60,018,826 $56.62 182
2020 Q4 23,961,301 $1,950,823,589 -$4,075,043 $81.47 175
2020 Q3 23,591,274 $1,680,536,565 -$20,350,025 $71.25 167
2020 Q2 23,674,634 $1,946,481,911 +$153,365,957 $82.28 185
2020 Q1 22,668,790 $1,334,380,347 +$44,013,550 $58.83 157
2019 Q4 22,285,098 $2,303,381,131 +$375,514,879 $103.36 168
2019 Q3 18,827,468 $381,090,444 +$9,017,673 $20.24 107
2019 Q2 18,262,766 $470,260,553 +$100,176,285 $25.75 105
2019 Q1 14,726,198 $209,549,043 +$159,033,578 $14.23 63
2018 Q4 3,826,666 $10,790,008 +$478,883 $2.82 35
2018 Q3 3,533,711 $12,193,010 -$1,993,494 $3.45 33
2018 Q2 4,098,087 $13,112,972 -$305,657 $3.20 34
2018 Q1 4,234,235 $10,372,895 -$6,118,939 $2.45 35
2017 Q4 5,822,045 $32,606,017 -$1,045,993 $5.60 33
2017 Q3 6,009,091 $33,278,940 -$2,135,111 $5.55 26
2017 Q2 6,403,643 $35,251,289 -$6,151,045 $5.50 33
2017 Q1 7,262,941 $28,323,589 +$5,379,688 $3.90 46
2016 Q4 6,160,435 $41,582,505 -$1,002,295 $6.75 40
2016 Q3 6,308,290 $49,689,460 +$4,018,384 $7.88 36
2016 Q2 5,799,374 $43,724,574 +$3,925,451 $7.54 34
2016 Q1 5,260,385 $45,240,000 +$313,031 $8.60 17
2015 Q4 5,216,906 $47,654,000 +$47,654,049 $9.25 11